and quinidine afforded high protection against ventricular fibrillation in hypothermia.
The over-all survival was limited by the development of acute heart failure in many treated animals that escaped ventricular fibrillation, but this could be overcome by inotropic agents.
Kline and Dreifus and their associates7+s observed that in dogs intravenous antazoline caused a transient reduction in cardiac output and a rise in peripheral resistance, with the blood pressure and heart rate remaining constant.
In clinical trials among 112 patients with 141 disturbances of rhythm they found antazoline to be an effective, well tolerated antiarrhythmic agent which was useful in the therapy of ectopic beats of atrial, nodal or ventricular origin. It was ineffective in the conversion of atria1 flutter and atria1 fibrillation.
Thus, animal studies and preliminary clinical trials provided evidence that antazoline has antiarrhythmic actions in addition to its known antihistamine effects.
Because the preliminary studies were encouraging, it was felt that further trials in many different kinds of disturbances of cardiac rhythm were indicated.
MATERIAL AND METHODS
The present series consisted of 115 patients with 137 cardiac arrhythmias selected from the medical and surgical wards of the University of Michigan Hospital, the Heart Station and the Ann Arbor Veterans Hospital. With the exception of patients with atria1 fibrillation and atria1 flutter, some of whom were not included in the study, the selection represented no known bias toward any one group. No other conditions were so handled, and the number of patients with other arrhythmias approximately represented their incidence during the period of the study. To avoid eliminating those patients who might not respond or who might have early side effects, no patients were dropped from the study because of poor follow-up or inadequate data.
More than one half of the patients were over 59 years of age. There was no associated heart disease in 25 patients; 45 had coronary artery disease; 10 had rheumatic heart disease; and the remainder had miscellaneous kinds of heart disease. There were 13 deaths, and 9 postmortem examinations were made. None of the deaths could be attributed directly to antazoline, but all occurred in patients in the terminal phase of their disease.
All patients were evaluated by one or more of the authors during periods of hospitalization and in the follow-up visits to the Heart Station.
There the arrhythmia was investigated by reviewing the patient's report card with him to determine the dates, duration and frequency of paroxysmal arrhythmias and by taking a three-minute count of the number of premature beats and/or monitoring their frequency with a recording cardiotachometer for from 15 minutes to 24 hours.
Where circumstances permitted, a control period and/or trial on another antiarrhythmic agent for an equal or greater period was used in lieu of placebo 
RESULTS
Abolition of cardiac arrhythmias, prevention of paroxysms of rapid heart action and the prevention of premature beats are separate aspects of this study and will be considered separately.
ABOLITION OF ABNORMAL RHYTHM
Attempts were made to terminate abnormal cardiac rhythm in 19 patients, and the results are listed in Table I .
Atria1 Flutter and Fibrillation:
Conversion of atria1 flutter or atria1 fibrillation was attempted 11 times in 10 patients, both conditions occurring in 1 patient at different times.
There was one successful conversion of each.
Of the 4 patients in whom unsuccessful attempts were made to terminate atria1 flutter, 3 received only oral medication with multiple dosage schedules of 100 or 200 mg. every one or two hours for six doses.
The one success occurred in a 70 year old woman with thyrotoxicosis given 350
T"hg.
intravenously, with prompt conversion. e patient died one week later, possibly due to an overdose of chloral hydrate and other causes.
All patients treated had slowing of the atria1 rate, whether or not conversion took place. . . In 7 patients in whom attempts to abolish atria1 fibrillation were made, only 6 received an adequate dosage. The seventh patient, treated early in the study, received only 200 mg. four times a day. Of the remaining 6, 1 received 400 mg. of antazoline intravenously in 22 minutes, and in addition to the oral schedules listed here, 1 received 1,500 mg. intravenously in 1 hour and 55 minutes, with only mild symptoms and without converting his rhythm. The one success was achieved in a 43 year old man who developed atria1 fibrillation during cardiac catheterization, which persisted for five days prior to the attempt at conversion, during which time he was fully digitalized. The effective dose was 100 mg. each hour for four doses. Normal sinus rhythm persisted after the conversion. The oral schedules used in the unsuccessful attempts were 100 or 200 mg. every one or two hours. In 1 case the schedule was 300 mg. every two hours for six doses.
Ventricular Tuchycardz'u: By far the best results were obtained in the abolition of ventricular arrhythmias. Out of 5 patients with ventricular tachycardia, 4 were converted to normal sinus rhythm, by using 400 to 600 mg. of antazoline diluted and given intravenously over a 30 minute period. The one failure was in an unconscious patient with fresh myocardial infarction and ventricular tachycardia who subse-VOLUME 14, OCTOBER 1964 quently died. Prior to death the QRS complexes became wide and were of sine wave configuration, resembling potassium intoxication. Figure 1 illustrates the sequence of a successful conversion of proved ventricular tachycardia.
Ventricular Fibrillation:
Two patients experienced cardiac arrest due to ventricular fibrillation, and it is felt that antazoline was effective in preventing a recurrence of this rhythm after electrical countershock conversion of the ventricular fibrillation. In one of these patients ventricular tachycardia developed after ventricular fibrillation was converted with electric countershock. The ventricular tachycardia was then treated by giving 200 mg. of procaine amide intravenously. Ventricular fibrillation recurred, and after a considerable period of cardiac massage, 100 mg. of antazoline was given intravenously, and the rhythm returned to a normal sinus mechanism within 10 minutes. Normal rhythm was maintained for two weeks, at the end of which the patient died of pulmonary complications.
The second patient had a fresh posterolateral myocardial infarction with ventricular fibrillation, which recurred after each of two attempts of electrical defibrillation. Antazoline, 600 mg., was given intravenously, and the thiid electrical conversion was successful in that normal sinus rhythm persisted. It is obvious that antazoline was usefui only in conjunction with alternating current defibrillation, but both of these encouraging outcomes would seem to justify further study of antazoline in ventricular fibrillation.
PREVENTION OF PAROXYSMAL ARRHYTHMIAS
Evaluation of the ability of antazoline or an) antiarrhythmic agent to prevent attacks of rapid heart action is most difficult, for the groups studied were not homogeneous in any sense except for the rhythm disturbance itself. The frequency of attacks, presence of heart disease, age group and presence of associated anxiety are all factors that cannot be eliminated by group study of the type described here. Thus, each patient had to serve as his own control.
The rhythm disturbances, with few exceptions, were so intermittent that they could not be documented, and so reliance had to be placed on a report card system. Figure 2 . illustrates how evaluation was made in a patient with many premature beats. The patient, a 58 year old white man, had a two year history of rapid heart action every two months.
He was admitted to the hospital following such an attack, during which he lost consciousness while driving and crashed into a tree.
The effective as quinidine in the prevention of premature beats in this patient.
Since the followup period was only one month, it was not felt proper to evaluate the effectiveness in the undiagnosed rapid heart action, although the patient was free of attacks during this period. The next 5 patients illustrate clinical situations where therapy of premature beats appeared justified to prevent the occurrence of a more serious arrhythmia. Figure 3 is a cardiotachometer record taken on a 60 year old man with paroxysmal ventricular tachycardia proved by electrocardiograms. In addition, he had frequent ventricular premature beats during the period of ineffective treatment with procaine amide. Antazoline was effective in suppressing both disturbances of rhythm. Figure 4 is a record from a 49 year old woman who had fresh myocardial infarction on the day the tracings were taken.
It shows two strips of electrocardiograms taken several hours apart and is representative of the clinical situation as observed over a two month period. Bigeminy, seen in the first tracing, was abolished by antazoline but recurred two months later when the drug was discontinued and ceased again when the drug was restarted.
It has not recurred in a further six month period of antazoline therapy.
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Figures 5 to 7 illustrate the value of continuously monitoring the heart rate of patients to evaluate both the dose (Fig. 5) and choice of drug ( Fig. 6 and 7) needed to suppress premature beats in patients with coronary artery disease.
Prevention of Paroxysmal Tachycardia: There were 10 patients with paroxysmal atria1 tachycardia. Of 2 in this group who had recurrent atria1 tachycardia due to digitalis intoxication, antazoline was effective in 1; the second patient was given other drugs such as potassium chloride making it quite impossible to evaluate any effects of antazoline other than the side reactions. The remaining 8 patients were followed up from 4 to 12 months (average, 7.7 months) to determine the frequency of recurrent attacks of atria1 tachycardia, and antazoline was found at least moderately effective in 3.
Antazoline .was used to prevent paroxysmal atria1 jutter in 6 patients on follow-up for an average of 8.9 months and in paroxysmal atria1 fibrillation in 8 patients followed for an average of 7.9 months.
One of these patients was followed for 21.5 months and had 18 attacks of atria1 fibrillation in 5l/2 months under no therapy, 5 attacks in 3 months of placebo therapy, and Tracings from a 69 year old woman with angina pectoris and almost constant atrial premature beats during the 24 hour control period (upper trace).
Alderlin, a beta adrenergic blocking agent, was slightly effective (middle trace). but antazoline was classed as the most effective. The dose, time of administration and ,, the time the record was taken are shown.
14 attacks in 13 months while receiving antazoline in 100 and 200 mg. doses four times a day. This was felt to be a significant reduction in number of attacks but was interpreted as only slightly effective. The effects of the drug in 1 of the patients with paroxysmal atria1 fibrillation could not be evaluated because he had received only the placebo before being lost to follow-up.
The results in another patient could not be evaluated because the paroxysmal atria1 fibrillation simply disappeared and failed to return after the drug was stopped. In 4 patients on follow-up for 3, 7, 14 and 17 months respectively, the drug was ineffective. One of these patients had an adequate quinidine trial, which was also ineffective.
Six patients with paroxysmal ventricular tachycardia were studied. In 1 of the patients in whom the drug was considered ineffective, ventricular premature beats could be suppressed by antazoline. In the 1 case in which the drug was moderately effective there was no known heart disease, but the patient experienced repeated attacks of syncope due to ventricular tachycardia over a 27 month period of observation. These attacks could not be prevented by quinidine sulfate, quinidine gluconate in a long-acting preparation or by procaine amide. Seven attacks of ventricular tachycardia were observed in one month. Antazoline in a dose of 100 mg. 4 times a day was also ineffective, VOLUME 14, OCTOBER 1964 but when the dose was increased to 200 mg. four times a day, the number of attacks was reduced to less than one a month (8 total in 10 months of observation on antazoline). be evaluated in the remaining 7 patients bccause of poor reporting. Xfzusca or vamiting, or both, constituted the chief side effect, and this could be prevented in most patients by taking the drug with meals or with an antacid preparation.
SIDE EFFECTS AND TOXIC REACTIONS
The second most frequent side effect was drowsiness, but it was not severe enough to necessitate stopping the drug.
Few severe side reactions were encountered, but these are worth reporting.
They were as follows: Chills and Fever: A 65 year old physician was given 100 mg. of antazoline four times a day as prophylaxis against frequent attacks of rapid heart action which, as judged by the history, resembled atria1 tachycardia. The number of attacks was reduced, but the patient had headache, chilliness, nausea and a temperature of 103.5" F.
The symptoms subsided completely when antazoline was stopped. One month later the drug was resumed, and after the patient took the second dose he again had nausea, chilliness and a temperature of 103.5" F. The white blood cell count was 10,000, with 16 per cent eosinophils.
The symptoms subsided when the drug was stopped.
One additional tablet was taken three months later, and the patient again had nausea, diarrhea and fever (101.5' F).
There was no history of asthma or hay fever in this patient.
Diarrhea occurred in only 5 per cent of the patients, but when it occurred it was often severe enough to necessitate stopping the drug. One case will illustrate this point:
A 66 year old woman had many ventricular premature beats occurring in runs, which constituted her "attacks." These were slightly reduced by actual count during antazoline therapy, and the drug was considered slightly effective after a 6 month study period.
Mild nausea and diarrhea were noted at the onset of therapy, but these symptoms were not severe enough to stop therapy.
By the fifth month the patient was having five to six watery stools daily.
When antazoline was stopped, the symptoms disappeared, only to recur when antazoline was given again.
Neurologic Side Ejects: Five patients had symptoms referable to the central nervous systern.
These symptoms were described as the "shakes" and consisted of uncontrollable tremor that occurred in 1 patient with a dose of 200 mg. four times a day and disappeared when the dose was reduced to 100 mg. four times a day. One patient experienced nausea and severe paresthesias of all four limbs following 350 mg.
of anlazoline given intravenously in 3 1 i minute injection for successful conversion of \-cntricular tachycardia to normal sinus rhythm. .L\nother patient, a 61 year old man with many ventricular premature beats, became profoundly depressed and had a clouded sensorium on 100 mg. of antazoline four times a day.
These symptoms disappeared, and the ventricular premature beats were controlled intermittently (result coded as ineffective) on a dose of 50 mg. four titnes a day.
A fourth patient, given 100 mg. of antazoline four times a day for frequent ventricular premature beats, experienced lightheadedness and muscle spasm of the legs.
A fifth patient, a 53 year old woman, had many atria1 and ventricular premature beats occurring in runs following repair of an atria1 septal defect.
She became disoriented when given 200 mg. of antazoline every six hours.
This symptom cleared after antazoline was stopped for two days.
Skin Eruption: A single patient had a marked scaling dermatitis of his hands and scalp after receiving 200 mg. of antazoline three times a day for four months.
These lesions cleared after the drug was stopped for two weeks.
SUMMARY
Antazoline is a comparatively safe and effective antiarrhythmic drug in many situations, for both the conversion and prevention of arrhythmias.
It appeared to be most effective in the abolition of ventricular tachycardia, possibly helpful in 2 cases of cardiac arrest due to ventricular fibrillation and beneficial in the prevention of atria1 and ventricular pretnature beats.
It was useful and deserves further trial in the prevention of paroxysmal ventricular tachycardia.
It was almost ineffective in the conversion and prophylaxis of atria1 flutter and atria1 fibrillation but appeared to be of value in the prevention of paroxysmal atria1 tachycardia.
There was a high incidence of mild side effects, mostly of the gastrointestinal type, some of which were prevented by taking the drug with meals or with an antacid preparation. No irreversible or serious side actions were encountered, but diarrhea, central nervous system symptoms and chills and fever necessitated stopping the drug in a small percentage of patients.
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